Catalyst Dossier · compiled by CeliA 🧫

Vera Therapeutics, Inc. (VERA)

Pharmaceutical Preparations · market cap $2.5B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vera Therapeutics (VERA) is a ~$3B market cap clinical-stage biopharma focused on immunological kidney disease, built almost entirely around atacicept for IgA Nephropathy (IgAN). The company faces a binary inflection point: a PDUFA date of October 6, 2026 for atacicept, preceded by a Phase 2 data readout estimated September 15, 2026. With only 3.2 months of cash runway reported, near-term financing risk is material regardless of regulatory outcome.

The catalyst path

2026-08-04Earningsimp 5/10
2026-09-15 (est.)Phase 2 · Ataciceptimp 7/10
2026-10-06PDUFA · Ataciceptimp 8/10

Pipeline

Asset	Phase	Indication
Atacicept	Phase 3	IgA Nephropathy (IgAN)
MAU868	Phase 2	BK Virus Infection

Price & technical context

3-month

+1.7%

6-month

-19.5%

12-month

+79.1%

52-wk range

$19.25–$55.67

vs 50-day MA

+13.9%

vs 200-day MA

+8.6%

Realized vol

57.1%

Max drawdown

-62.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VERA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.